Mitsubishi UFJ Asset Management Co. Ltd. Has $6.41 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 25.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 75,472 shares of the company’s stock after acquiring an additional 15,200 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.06% of Vaxcyte worth $6,405,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Vaxcyte by 4.6% during the fourth quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company’s stock worth $979,184,000 after acquiring an additional 521,204 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Vaxcyte by 23.1% during the third quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock worth $1,247,954,000 after acquiring an additional 2,052,989 shares in the last quarter. RA Capital Management L.P. grew its position in shares of Vaxcyte by 5.9% in the 3rd quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock valued at $992,914,000 after purchasing an additional 485,436 shares during the period. State Street Corp boosted its holdings in shares of Vaxcyte by 1.1% in the third quarter. State Street Corp now owns 3,405,743 shares of the company’s stock valued at $389,174,000 after buying an additional 38,596 shares during the period. Finally, Franklin Resources Inc. boosted its stake in Vaxcyte by 13.2% in the 3rd quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company’s stock worth $315,162,000 after purchasing an additional 324,560 shares during the period. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the transaction, the chief operating officer now directly owns 154,931 shares of the company’s stock, valued at $11,351,794.37. The trade was a 4.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Teri Loxam sold 6,250 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the transaction, the director now directly owns 7,175 shares in the company, valued at $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 46,250 shares of company stock worth $3,840,018. Company insiders own 3.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, February 26th. The Goldman Sachs Group started coverage on shares of Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 price objective on the stock. Finally, Guggenheim restated a “buy” rating and set a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Trading Down 45.6 %

NASDAQ:PCVX opened at $37.76 on Tuesday. The stock has a market capitalization of $4.86 billion, a PE ratio of -8.21 and a beta of 1.02. Vaxcyte, Inc. has a 1-year low of $30.12 and a 1-year high of $121.06. The firm has a fifty day simple moving average of $79.12 and a 200 day simple moving average of $91.83.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.14. On average, equities analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.